AbbVie Inc. (ABBV-N)

Skyrizi continues to work.

His best performer so far this year, up 12%. Well-managed. They replaced Humira with hit drugs and added key companies; pays a 3.2% dividend. 

It is a large cap biotech with a temporary pullback. Humera went off patent so there are some declines in revenue. He really likes the re-iteration of Humera which has taken off. Also it is re-designing a mistrial.          Buy 20  Hold 10  Sell 0

The drug companies are in the dog house. If you buy this, you must be patient. It yields 4%.

He added more AbbVie. Obviously, today's news about the disappointing drug trials is not good. This schizophrenia drug was projected to make $1.1 billion in sales four years from now. But today's share plunge is too great, overdone. He might add on even more weakness. Trades at 14x forward PE and pays a 3.9% dividend. It's a great company on sale. They have a long track record of making acquisitions.

Is one of the largest companies in bio-medicals. Growth has been impressive. Are expanding into neuro-science, Alzheimer's. They clearly replaced a key drug going off-patent with a good pipeline. Two anti-inflammatory drugs are outperforming expectations.

They beat top and bottom and raised guidance. A nice quarter. Their key drugs were way up. They have a strong pipeline.

Management has replaced key drug, Humira, and made key acquisitions. Are doing all the right things.

Have a great drug pipeline.

Abbvie is famous for Humira, now off-patent. They've done well filling that hole, but their growth rate is now tepid. So, he sold it.

Was upgraded today. It will continue to be a great stock and expects it to surpass $200. It trades at 2025 15x PE. It solved the problem and how to do after their big drug, Humira, comes off patent. They've replaced it with two other hit drugs that will top $20 billion in annual sales in 2025. Good valuation and pays a 3.3% dividend. They've made key pick-ups in neurology.

Is bullish biotech. Likes Abbvie for its diverse pipeline of drugs.

Done well with a best-selling arthritis drug. Strategically pivoted to other products to bolster revenue stream. Significant growth expected over next 5-10 years. Long-term hold. Increased guidance. Potential 8.5% upside from here.